共 50 条
- [1] Distribution analysis of S-222611 in brain metastases of HER2-positive breast cancer by quantitative imaging mass spectrometry: prospect for antitumor activity of EGFR/HER2/HER4 kinase inhibitor S-222611 against brain metastasesCANCER RESEARCH, 2017, 77Tanaka, YukariHirata, MichinariShinonome, SatomiMatsumoto, MitsunobuNogami, WataruTorii, MikinoriNezasa, Ken-ichiTanaka, Hidekazu
- [2] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastasesCANCER RESEARCH, 2016, 76Baird, R. D.Arkenau, H-TDeva, S.Cresti, N.Garcia-Corbacho, J.Hogarth, L.Frenkel, E.Kawaguchi, K.Arimura, A.Donaldson, K.Posner, J.Sarker, D.Jodrell, D.Plummer, R.Spicer, J.Italiano, A.
- [3] A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab plus /- chemotherapy in patients with HER2-positive metastatic breast cancerCANCER RESEARCH, 2017, 77Rafii, S.Macpherson, I.Baird, R.Saggese, M.Spiliopoulou, P.Kumar, S.Italiano, A.Bonneterre, J.Campone, M.Cresti, N.Posner, J.Takeda, Y.Arimura, A.Spicer, J.
- [4] Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancerCANCER RESEARCH, 2013, 73Baird, R. D.Cresti, N.Beddowes, E.Saggese, M.Flynn, M.Corbacho, J. GarciaGao, F.Lemech, C.Donaldson, K.Posner, J.Kawabata, I.Forster, M.Arkenau, H. T.Plummer, R.Jodrell, D.Spicer, J.
- [5] S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: in vitro kinase inhibition and antitumor activityCANCER RESEARCH, 2009, 69Hirata, MichinariTanaka, HidekazuDohi, KeijiIguchi, MotofumiWada, TohruMatsuo, KenjiKume, MasaharuOmori, NaokiTada, YukioOrita, SatoshiAbe, KenjiArimura, AkinoriMatsuo, YoshiyukiKato, Akira
- [6] S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: In vivo antitumor effectsCANCER RESEARCH, 2009, 69Iguchi, MotofumiTanaka, HidekazuWada, TohruHojo, KanjiShinonome, SatomiSato, NorihitoNezasa, Ken-ichiOrita, SatoshiAbe, KenjiArimura, AkinoriMatsuo, YoshiyukiKato, Akira
- [7] Brain metastases in HER2-positive breast cancerLANCET ONCOLOGY, 2013, 14 (03): : 185 - 186Lin, Nancy U.
- [8] HER2Δ16 expression in HER2-positive breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)De Yao, Jocelyn TorresSun, DanyuGalehouse, DonnaShorten, ScottHaller, NairmeenRehmus, Esther Hoogland
- [9] HER2Δ16 expression in HER2-positive breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)De Yao, Jocelyn TorresSun, DanyuGalehouse, DonnaShorten, ScottHaller, Nairmeen AwadRehmus, Esther Hoogland
- [10] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Deva, SanjeevBaird, Richard D.Cresti, NicolaGarcia-Corbacho, JavierHogarth, LindaFrenkel, Eugene P.Kawaguchi, KeikoArimura, AkinoriDonaldson, KirsteenPosner, JohnSarker, DebashisJodrell, Duncan IanPlummer, RuthSpicer, James F.